Small Cap Feast
Small Cap Feast – 21st October 2016
Dish of the Day:
No AIM Primary Today
No AIM Primary Today
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
Filta— Schedule One from the provider of a number of services to national and independent commercial kitchen operators and owners. Targets early November listing. Capital raising plans as yet undisclosed
TI Van Elle—The geotechnical contractor to the UK construction market is hoping to come to AIM later this month
Ascot Lloyd— The UK IFA is also hoping to join AIM later this month. Ascot Lloyd’s strategy is to grow through a combination of organic growth and further targeted acquisitions.
Bagir Group (BAGR.L) 3.5p £1.77m
Trading update from designer, creator and provider of innovative tailoring. ‘2016 continues to be a successful year for Bagir. We are trading in line with market expectations for this financial year and we are making significant progress under our strategic plan to maintain this momentum across the business into 2017 and beyond.‘ EGM today to approve £6.4m placing. FYDec16E revenue of £48.16m and pre-tax loss of £2.29m.
Immunodiagnostic Systems (IDH.L) 207.5p £61.04m
H1Sep16 trading update from the specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market. Revenue is expected to be £19.5m vs £19.4m. On a like for like basis (i.e. at constant scope and constant exchange rates) revenue decreased 9%. Cash of £28.7m. The focus is on improving sales processes and capabilities, and strengthening the product pipeline through internal development and external partnerships. The next intermediate goal is to stabilise revenue on a like for like basis.
Time Out Group (TMO.L) 141p £183.3m
The global multi-platform media and e-commerce business with food & cultural markets, is pleased to announce it has acquired YPlan, on a debt free cash free basis. London-based YPlan is the “mobile-first” events discovery and booking platform. It offers a mix of event tickets on its app and website allowing people to discover and book things to do in the city. The consideration is £1.6m payable in TMO shares. The transaction is expected to be mildly dilutive to Time Out’s earnings in the current financial year and broadly neutral in 2017. There are no forecasts in the market.
Michelmersh Brick Holdings (MBH.L) 63p £51.18m
Q3 trading update from the specialist brick manufacturer & landfill company. The UK brick market has been experiencing falling output and a small increase in despatch volumes as manufacturers respond to market demand. Anticipated price increases have been difficult to put through. FY expectations revised to be in line with 2015 (£29.07m revenues, EPS 4.44p vs current consensus of £31.9m and 4.9p). Order book remains strong, 5% ahead of H1 & cost savings identified that help to mitigate the effect of negative market trends.
Starcom (STAR.L) 2.62p £3.57m
The technology company specialising in the development of wireless solutions for the remote tracking, monitoring and protection of a variety of assets and people, has conditionally raised £300,000 with new and existing shareholders at a price of 2.5p. The proceeds of will be used to provide the Company with additional working capital. The Board is increasingly confident that Starcom will at least meet the expectations, outlined at the time of the interims, for improvement in revenues for 2016. FY16E revs £4.87m and breakeven PBT.
Abzena (ABZA.L) 42p £57.59m
The life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that Gilead Sciences, Inc. has announced top line Phase II clinical study results of its product, GS-4997 (selonsertib) in combination with the investigational monoclonal antibody, simtuzumab (SIM) or SIM alone, in patients with non-alcoholic steatohepatitis (NASH). GS-4997 demonstrated anti-fibrotic activity in an open-label Phase 2 clinical trial that included 72 patient.
Trinity Capital (TRC.L) 1.75p £3.68m
The boutique investment banking firm has conditionally agreed to dispose of all remaining assets held jointly with Immobilien Funds for approximately £8.8m. The agreement requires that the main disposals be concluded within eight weeks, failing which it will terminate. The Company will make a further announcement to Shareholders as and when it has further clarity regarding the completion of the disposals of assets.
European Metals Holdings (EMH.L) 29.88p £37.02m
‘Outstanding lithium recoveries’ during the on-going pre-feasibility study at Cinovec in the Czech Republic. Wet magnetic separation achieved a near pure lithium mica concentrate grading 2.85% Li2O with a lithium recovery of 92%. Lithium recoveries are 10-15% higher than those achieved via floation in scoping study. Total Indicated Resource of 49.1Mt @0.43% Li2O & Inferred Resource of 482Mt @0.43% Li2O containing combined 5.7 Mt Lithium Carbonate Equivalent; the largest in Europe.
DX Group (DX.L) 88p £37.6m
The independent parcels, mail and logistics operator, notes today’s announcement by the UK Competition and Markets Authority regarding the Company’s acquisition of the trade and assets of The Legal Post (Scotland) Limited and First Post Limited. The CMA has confirmed that its investigation into the acquisition is now closed and that no further action will be taken. Targeting full integration by end of 2016. FYJun17 revenues of £297.6m and 4.83p EPS. Dividend 2.5p.
RTC Group (RTC.L) 53.5p £7.78m
Trading update from the company engaged in the recruitment of human capital resources and the provision of managed services. Whilst trading in H116 was in line with expectations, H2 has seen delays in the commencement of infrastructure projects affecting the short term performance of ATA, primarily in their permanent vertical market activities. Consequently full year results are expected to be lower than current market expectations. FYDec16E £71,6m rev and £1.6m PBT. Delayed projects expected to start in near future.
Emily Liu, CFA, CAIA
0203 764 2344
0203 764 2345
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.